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A  report on the Third Annual International Conference on
Transposition and Animal Biotechnology, Minneapolis, USA, 23-
24 June 2005, and the FASEB Summer Research Conference
‘Mammalian Mobile Elements’, Tuscon, USA, 4-9 June, 2005.
Transposons are mobile genetic elements with the ability to
move to new sites in host genomes. This mobility gives them
awesome potential as genome-altering tools for somatic and
germline mutagenesis, and as gene-delivery tools in the lab-
oratory and for gene therapy. Two meetings on transposons
this summer, in Minneapolis and Tucson, revealed the
impressive progress in this field, with emphasis on trans-
posons in vertebrates. The following report describes a few
of the highlights from these meetings.
Transposable elements are classified as either DNA trans-
posons or retrotransposons on the basis of their mode of
transposition. Eukaryotic DNA transposons transpose by a
conservative ‘cut-and-paste’ mechanism; this group includes
the Tc1/mariner, hAT, P-element, piggyBac, Mutator, and
En/Spm families. Retrotransposons replicate via an RNA
intermediate by a ‘copy-and-paste’ mechanism, and are
further subdivided into long terminal repeat (LTR)- and
non-LTR types. LTR-retrotransposons are widely distrib-
uted among diverse eukaryotes. Phylogenetic analyses based
on reverse transcriptase indicate the existence of at least
four distinct lineages of LTR-retrotransposons, and five
groups of non-LTR retrotransposons. The list is expanding
as more organisms are being sequenced and analyzed.
Russell Poulter (University of Otago, Dunedin, New
Zealand) reported his group’s recent identification of an
array of transposable elements in fungi and vertebrates, and
presented compelling genetic evidence that Zorro-3, a retro-
transposon-derived L1 element from Candida albicans, was
still transpositionally active.
The Sleeping Beauty transposon
A star of both meetings was the Sleeping Beauty (SB) DNA
transposon, a vertebrate member of the Tc1/mariner family
that was resurrected from defective ancient elements through
site-directed mutagenesis in 1997. SB is typically used as a
two-component system: one component is a gutted transpo-
son carrying a reporter gene(s) and/or other molecular bells
and whistles, flanked by the inverted repeats containing
transposase-binding sites; the second is the SB transposase
expressed under the control of a heterologous promoter,
which is necessary and sufficient for transposition. The trans-
position process is not, however, independent of the state of
the host cell. Zoltan Ivics (Max Delbruck Center for Molecular
Medicine, Berlin-Buch, Germany), who originally revived
Sleeping Beauty, reported that SB transposition may be coor-
dinated with cell-cycle control. It is well known that cyclin D1
is a key regulatory factor that promotes cell-cycle progres-
sion from G1 to S phase. Interestingly, a reduction of cyclin
D1 expression level was observed when SB transposase was
overexpressed in human cells, resulting in an extended G1
phase. The molecular mechanism for downregulation of
cyclin D1 by SB transposase is being characterized.
The transposition activity of SB has been the focal point of
many studies. The element transposes efficiently in a variety
of vertebrate cell lines, in mouse somatic tissues, and in the
mouse germline, but, unlike retrotransposons, many sites of
SB insertion cluster in the vicinity of its chromosome of origin,
a phenomenon termed ‘local hopping’. To further improve SB
transposition activity, SB is being engineered: mutation of the
transposase-binding sites and searches for more active ver-
sions of the transposase are both being attempted. The stakes
for optimization are high, as even a twofold increase in activity
could translate into a significant improvement, for example in
the efficacy of SB for gene therapy or mutagenesis. This was
exemplified by Bradley Fletcher (University of Florida,
Gainesville, USA), who reported efforts to develop a moreactive SB vector system for gene therapy by combining indi-
vidual improvements discovered by different groups. The new
SB system displayed a substantial 16-fold increase in transpo-
sition efficiency as compared to the original system in cultured
cells, but when it was tested as a non-viral gene-delivery
vehicle in mice only a modest twofold increase of transgene
expression was achieved.
Cancer gene discovery and germline
mutagenesis
In less than a decade, researchers have successfully adapted
the  SB system to several major applications in vertebrate
genomics, summarized by David Largaespada (University of
Minnesota, Minneapolis, USA) as germline transgenesis,
somatic transgenesis (gene therapy), germline insertional
mutagenesis, and somatic cell mutagenesis (Figure 1).
Perhaps the most dramatic breakthrough is in somatic cell
mutagenesis and its application to the discovery of potential
oncogenes, as illustrated in two presentations at the Min-
neapolis conference. Previously, the limited activity of SB in
cultured cells and limited evidence for active somatic trans-
position in vivo had prevented its use for identifying tumori-
genic genes. This barrier has now been broken by the design
of more effective mutagenic SB by two collaborating
research groups using different approaches. Adam Dupuy
(National Cancer Institute, Frederick, USA) has incorpo-
rated several proven designs into his system. The transposon
itself was first designed to disrupt the expression of an
endogenous gene independent of insertion orientation; the
new vector also included retroviral enhancer/promoter
sequences well known to activate oncogenes, and it had opti-
mized transposase-binding sites and overall size. Second,
founder mouse lines with the highest number of unmethy-
lated transposon copies were selected. Finally, a single-copy
knock-in line for an improved SB transposase (ROSA-SB11)
was constructed, providing ubiquitous and consistent trans-
posase expression. The first sign of success was embryonic
lethality in the transposon/transposase double-transgenic
lines. By 6 weeks after birth, evidence suggests that the
donor copies had virtually all excised from the original inte-
gration site and jumped to other genomic locations. The
double-transgenic mice were tumor-prone, with high pene-
trance (the proportion showing a mutant phenotype); by 17
weeks all had succumbed to tumors. On examination, all the
tumors contained clonal or subclonal SB insertions.
Remarkably, in this study there was little evidence for local
hopping, perhaps because the selection for tumors was so
strong that rare insertions with strong tumorigenic potential
predominated, and/or because transposition rates were so
high that there were multiple rounds of transposition in each
cell; modeling suggests that multiple rounds of transposition
would rapidly reduce the impact of local hopping. It is
notable that tumors were induced in a genetic background
not predisposed to cancer, demonstrating the feasibility and
power of using SB transposon technology in cancer gene
discovery. One disappointment was that the tumor spectrum
included a preponderance of lymphomas. This may reflect
the tropism of the retroviral enhancer/promoter used, or
may simply be because hematopoietic stem cells constitute
the largest target of self-renewing stem cells in the body.
This bias in the tumor spectrum can probably be overcome
by tissue-specific expression of SB transposase.
Lara Collier (University of Minnesota, Minneapolis, USA)
reported the use of a complementary strategy - SB-induced
formation of solid tumors in a sensitized p19/Arf mutant
mouse line that is predisposed to cancer owing to a deficiency
of the Arf tumor suppressor. Retrovirus-mediated mutagene-
sis screens had previously shown a predisposition to
hematopoietic cancers, and to a lesser extent to mammary
cancer, but to few other types. Cancer researchers have been
waiting for an alternative mutagenesis system to identify
genes involved in solid tumor formation. Collier’s SB system
features a similar transposon vector to Dupuy’s, with gene-dis-
rupting elements and the identical retroviral enhancer/pro-
moter,  but with a seemingly less aggressive transposase
(CAGGS-SB10). In contrast to Dupuy’s study, mice doubly
transgenic for this transposon/transposase combination did
not show increased cancer susceptibility for more than a
year after birth. This changed when the system was crossed
into the p19/Arf mice; time to morbidity was significantly
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Figure 1
Four major applications of transposon technology in vertebrate functional
genomics. The four organisms surrounding the DNA transposon indicate
that certain transposons, such as elements belonging to the mariner family,
can be used in a broad range of hosts as their movement is largely
independent of host functions. (a) Most transposons can disrupt host
genes upon insertion. Such insertions can be somatic insertions, which can
be used to discover and analyze cancer genes, or germline insertions
resulting in heritable mutations that produce phenotypic change in the
progeny. (b) Transposons can also be used to deliver exogenous genes
into the organism through somatic cell transgenesis (in gene therapy) or
germline transgenesis (producing transgenic animals at high efficiency).
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(a) (b)shortened in the SB animals compared with control p19/Arf-
deficient mice. Over 95% of mice from the experimental
group in which transposons were mobilizing in the soma
succumbed mainly to soft-tissue sarcoma or osteosarcoma in
one year compared with around 70% in the controls. One of
the common insertion sites is a known oncogene, Braf,
which was hit in around 80% of the sarcomas. Analysis of
the insertions revealed an approximately twofold higher rate
of local hopping compared to Dupuy’s work, presumably
reflecting the lower frequency of multiple cycles of transpo-
sition in Collier’s study. So far, no direct comparison has
been made between the two systems regarding actual trans-
position frequencies, transposase expression levels, and
mutational patterns. Thus, it remains a mystery as to how
much the various components in the two studies contributed
to the discrepancies of cancer susceptibility in the wild-type
background. Collier’s work nevertheless represents a power-
ful complementary strategy for discovering genes operating
in a specific pathway(s) in a sensitized background.
Significant developments are also being made in germline
mutagenesis using SB in the mouse. Earlier work suggested
that local hopping is most pronounced for SB transposition
in the mouse germline. The obvious implication of this is
that to achieve unbiased insertion throughout the whole
genome, one has to start with a number of independent
transgenic lines in which the transposon concatemer is
located on different chromosomes. On the other hand, this
phenomenon can be exploited for region-specific saturation
mutagenesis, as shown in two presentations. Aron Geurts
(University of Minnesota, Minneapolis, USA) reported
progress on an SB-based forward-genetic screen in the
mouse germline. A balancer strain was used to recover reces-
sive lethal mutations and to facilitate a three-generation
screening process. More than ten pedigrees with recessive
lethal phenotypes and one with a very specific dominant viable
polydactyly phenotype were identified. Chikara Kokubu
(Osaka University, Osaka, Japan) presented a very elegant
exploitation of SB local hopping to engineer a nested series
of deletion mutations which he then applied to region-spe-
cific mapping of cis-regulatory elements (for example,
enhancers and insulators) in the complex Pax1 gene locus of
the mouse genome.
The transposon technology toolkit
Although SB is the current bright star, other transposons are
also being developed into useful functional genomics tools,
such as the fish DNA transposon Tol2, the mouse LTR-retro-
transposon IAP and the mammalian non-LTR retrotranspo-
son L1 from human and mouse. Tol2 belongs to the hAT
family of DNA transposons, and is so far the only known nat-
urally occurring active DNA transposon in vertebrates.
When tested in transgenesis, the germline transmission fre-
quency by the Tol2 system is slightly higher than that by the
current  SB counterpart. Koichi Kawakami (National Insti-
tute of Genetics, Shizuoka, Japan), who first identified a
functional Tol2 transposase, discussed the use of the Tol2
transposon system in efficient gene and enhancer trapping
in zebrafish, and has characterized scores of fish lines with
unique expression patterns for the green fluorescent protein
(GFP) reporter. Vladimir Korzh (Institute of Molecular and
Cell Biology, Singapore) on the other hand elaborated on a
range of downstream research applications that may be
applicable to existing Tol2-mediated enhancer trap zebrafish
lines. Such examples include the potential use of the GFP
reporter in some lines as a built-in in vivo histological
marker, which can be very useful in tracking single cell fate
and/or for morphological studies. In addition, the existing
copies of SB may serve as ‘launching pads’ for further trans-
position events in somatic tissues if transposase mRNA is
supplied by injection.
Kyoji Horie (Osaka University, Osaka, Japan) introduced a
new player to the transposon technology field. This is an IAP
element initially isolated from a mouse tumor cell line; it
shows high transposition activity in cultured cell lines but
has not yet been shown to transpose in mice. Currently, the
potential mechanism of IAP silencing in transgenic mice is
being explored. Eric Ostertag (University of Pennsylvania,
Philadelphia, USA) presented an update on the characteriza-
tion of human L1-mediated insertions in mice, building on
his previous demonstration of the active transposition of
human L1 in the mouse germline. One of us (J.D.B.) pro-
vided initial evidence that a synthetic mouse L1 retrotrans-
poson had high transposition activity in mice. Confirming
previous observations from cell-culture-based experiments,
neither Ostertag nor ourselves detected any significant bias
in integration-site selection by L1 retrotransposons in vivo,
which is in sharp contrast to the local hopping by SB,
demonstrating the special value of L1 as an additional gadget
in the transposon technology toolkit.
In a truly unexpected development that suggests a potential
role for natural L1 elements in mammalian biology, Alysson
Muotri from Fred Gage’s laboratory (The Salk Institute, La
Jolla, USA) described the alteration of neuronal gene expres-
sion in an L1 transgenic mouse line, and provided a provoca-
tive potential connection between L1 retrotransposition and
neural somatic mosaicism. Because the notion of ‘function
benefiting the host’ is anathema to the ‘selfish’ nature of
active mobile elements, this interesting study stimulated
extensive discussion.
One of the dilemmas for mouse functional genomics
researchers is that, for technical and historic reasons, there
has been no uniform standard for which mouse strains or
genetic background are used in experiments, although
C57BL/6 is the obvious candidate, as it has been sequenced.
The yeast (Saccharomyces cerevisiae) community found
itself in the same predicament a decade ago when the yeast
sequence was completed: a sequence of one strain but a
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biology. A concerted community effort was made to con-
struct a uniform mutational resource, the yeast knockout
(YKO) collection in the sequenced strain background. The
YKO resource has been wildly successful, and is the starting
point for virtually every genetic screen done today; it pro-
vides the uniform background that can then be embellished
by ‘genome artists’ working in outlying strains of yeast. 
The time has come for the mouse functional genomics
community to make a similar bold move. Currently, mouse
functional genomics is sharply divided between those who
use chemical mutagenesis, such as ethylnitrosourea
(ENU) mutagenesis, and those who use gene-trapping.
Both these approaches are extremely useful, but also have
severe limitations: ENU mutations are not easily mapped,
and gene-trapping is done in tissue culture, not directly in
the mouse. The efforts of groups using these approaches
have been piecemeal and disparate, and there has been no
effort to provide a mutational resource in a uniform
genetic background. The opportunity is here to use the
transposon toolbox as part of a community effort to gener-
ate a public mouse insertional mutation resource, without
the costs of working with embryonic stem cells, but using
simple breeding approaches and with the tremendous
benefit that each mutation is tagged and can thus easily be
mapped. Transposon technology has great potential in ver-
tebrate functional genomics, and as the transposon toolkit
is rapidly expanded, we hope to see advances in many
important areas, including gene therapy, cancer modeling
and gene discovery, in the near future.
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